)
Visual
test
IGM Biosciences
IGM Biosciences (IGMS) investor relations material
IGM Biosciences has been acquired
IGM Biosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary31 Jul, 2025
Executive summary
Entered into a Merger Agreement with Concentra Biosciences, with closing expected in August 2025, subject to conditions including minimum net cash and shareholder tender.
Terminated all product development activities and closed all lab and office facilities following major restructurings in January and April 2025.
Sanofi collaboration agreement was fully terminated in June 2025, resulting in recognition of all remaining deferred revenue.
No current product candidates in development; future activities depend on outcome of the Merger.
Financial highlights
Net income of $97.6 million for Q2 2025, compared to a net loss of $47.9 million in Q2 2024, driven by non-cash revenue from Sanofi agreement termination.
Collaboration revenue of $143.6 million in Q2 2025, up from $1.3 million in Q2 2024, due to full recognition of deferred revenue.
Research and development expenses decreased to $5.9 million in Q2 2025 from $42.0 million in Q2 2024, reflecting program wind-downs and workforce reductions.
Impairment and disposal of long-lived assets charges of $31.9 million in Q2 2025, related to lease terminations and asset disposals.
Cash, cash equivalents, and marketable securities totaled $104.3 million as of June 30, 2025.
Outlook and guidance
Expenses and operating losses expected to decrease following restructuring and Sanofi agreement termination.
If the Merger is not completed, the board may pursue dissolution or liquidation.
No plans to develop new product candidates unless the Merger is not completed and a new strategy is adopted.
List CVR-eligible product candidates and patents.
Quantify R&D expense reduction by cause?
What is the plan if the merger is not completed?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebMAGN
Q1 net sales $792M, Adjusted EBITDA $93M; 2026 targets 9% EBITDA growth, $100M FCF, $100M debt cut. - 5 FebLADR
Q4 2025 distributable earnings hit $21.4M, with investment-grade status and strong loan growth. - 5 FebAMSC
Record Q3 revenue and net income driven by tax benefit, acquisitions, and strong demand. - 5 FebKKR
Record fundraising, earnings, and new sports investing platform drive strong 2025 results. - 5 FebLIN
Record EPS, strong cash flow, and 6–9% 2026 growth outlook led by clean energy and electronics. - 5 FebROAD
Q1 revenue up 44%, record backlog, and raised FY26 outlook on strong Sunbelt demand. - 5 FebOESX
Raised FY 2026 revenue outlook and delivered fifth straight quarter of positive Adjusted EBITDA. - 5 FebTWI
AI-driven innovation and LSW tire success position the business for growth amid market challenges. - 5 FebREAL
All resolutions passed, with management emphasizing growth, market share, and financial stability. - 5 FebQGEN
2025 results beat expectations with strong growth pillars and robust 2026 outlook.
IGM Biosciences
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
IGM Biosciences Inc. is a clinical-stage biotechnology company focused on developing a new class of antibody medicines. Using the inherent advantages of the Immunoglobulin M (IgM) antibody structure, IGM Biosciences aims to create "super antibodies" for the treatment of cancer, as well as autoimmune and inflammatory diseases. By reimagining antibody medicines, the company believes it holds the world's most advanced research and development program for engineered therapeutic IgM antibodies. This approach seeks to expand upon and enhance the natural qualities of IgM antibodies, enabling the development of therapeutic antibodies designed to address a range of diseases more effectively. The company's pipeline includes multiple product candidates in various stages of clinical trials, targeting a variety of cancers and diseases through collaborations and license agreements to advance their research and potential treatments. IGM Biosciences is headquartered in Mountain View, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage